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Objective: To determine whether early identification of physiologic variances as-
sociated with interstage death would reduce mortality, we developed a home
surveillance program.
Methods: Patients discharged before initiation of home surveillance (group A, n 63)
were compared with patients discharged with an infant scale and pulse oximeter (group
B, n  24). Parents maintained a daily log of weight and arterial oxygen saturation
according to pulse oximetry and were instructed to contact their physician in case of an
arterial oxygen saturation less than 70% according to pulse oximetry, an acute weight
loss of more than 30 g in 24 hours, or failure to gain at least 20 g during a 3-day period.
Results: Interstage mortality among infants surviving to discharge was 15.8% (n 
9/57) in group A and 0% (n  0/24) in group B (P  .039). Surveillance criteria
were breached for 13 of 24 group B patients: 12 patients with decreased arterial oxygen
saturation according to pulse oximetry with or without poor weight gain and 1 patient
with poor weight gain alone. These 13 patients underwent bidirectional superior cavo-
pulmonary connection (stage 2 palliation) at an earlier age, 3.7  1.1 months of age
versus 5.2  2.0 months for patients with an uncomplicated interstage course (P 
.028). A growth curve was generated and showed reduced growth velocity between
4 and 5 months of age, with a plateau in growth beyond 5 months of age.
Conclusion: Daily home surveillance of arterial oxygen saturation according to
pulse oximetry and weight selected patients at increased risk of interstage death,
permitting timely intervention, primarily with early stage 2 palliation, and was
associated with improved interstage survival. Diminished growth identified 4 to 5
months after the Norwood procedure brings into question the value of delaying stage
2 palliation beyond 5 months of age.
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Despite improved early outcomes afterstage 1 palliation (S1P) for hypoplasticleft heart syndrome (HLHS), there con-tinues to be a 10% to 15% incidence oflate death before stage 2 palliation (S2P),creation of the bidirectional cavopulmo-
nary connection.1,2 Recurrent, residual, or progressive le-
sions after S1P that have been linked to interstage death
include restrictive atrial septal defect, neoaortic arch ob-
struction, systemic to pulmonary artery shunt stenosis, pul-
monary artery distortion, coronary insufficiency, and atrio-
ventricular valve insufficiency.3 Despite modifications of
surgical technique and medical interventions, significant
interim mortality continues to be associated with these
anatomic lesions, which lead to progressive hypoxemia and
impaired myocardial performance. In addition, hypovole-
mia and worsening hypoxemia related to common child-
hood illnesses are also associated with mortality among
infants after S1P.4 To determine whether early identification
of physiologic variances related to either anatomic changes
or medical disease would reduce interstage mortality, we
developed a home surveillance program for this at-risk
population by enlisting parents to monitor daily arterial
oxygen saturation via pulse oximetry (SpO2) and weight at
home between S1P and S2P.
Patients and Methods
Patients
Children’s Hospital of Wisconsin institutional review board ap-
proval was obtained to assess the efficacy of a home surveillance
program. Cohorts were created from all patients (n  87) who
underwent S1P for HLHS or a variant of HLHS at Children’s
Hospital of Wisconsin from July 1996 to November 2001. There
were 63 patients in group A (July 1996 through September 2000),
of whom 57 survived to hospital discharge after S1P and served as
control subjects before initiation of the home surveillance pro-
gram. The intervention group, group B (September 2000 through
November 2001), included 24 patients, all of whom survived to
hospital discharge after S1P and participated in the home surveil-
lance program until returning for S2P.
Discharge Criteria
All patients were monitored with continuous pulse oximetry before
discharge, with a target SpO2 of greater than 75% both awake and
asleep. If necessary, patients were given oxygen to achieve this
goal and discharged home with supplemental oxygen. If unable to
take in a full diet (110-130 kcal/[kg · d]) orally, a gastrostomy tube
was placed to provide caloric supplementation; 1 patient was
discharged home with a nasogastric tube in place. Digoxin was
prescribed for all patients. Afterload reduction with captopril and
diuretic therapy with furosemide were initiated with weaning of
inotropic support and used selectively for those patients demon-
strating an elevated pulmonary to systemic flow ratio greater than
2.0 (Q˙ p/Q˙ s  2.0) in the early postoperative period. Medical
therapy was adjusted on an outpatient basis at the discretion of the
treating cardiologist. Cardiologists practicing at Children’s Hospi-
tal of Wisconsin followed up 93% of patients in group A and 67%
of patients in group B.
Home Management
Parents of group A patients received the usual discharge instruc-
tions, including directives to contact their children’s physician for
respiratory or gastrointestinal illness, respiratory difficulties
(tachypnea, accessory muscle use, nasal flaring, distress), and
changes in perfusion (cool extremities, dusky or ashen appear-
ance). Other than scheduled follow-up with the cardiologist every
2 to 4 weeks, no additional home surveillance was performed in
group A. In addition to the usual discharge instructions, patients in
group B were sent home with digital infant scales sensitive to
changes of 10 g (Baby Checker Scale; Medela, McHenry, Ill) and
pulse oximeters (Nellcor 200; Nellcor Puritan Bennett Inc, Pleas-
anton, Calif). Parents were asked to record weight and SpO2 in a
daily log. Thresholds for parents to seek medical advice included
resting SpO2 less than 70%, weight loss of 30 g or failure to gain
20 g of weight during 3 days. Patients who breached surveillance
criteria underwent physician evaluation within 24 hours.
Data Analysis
A prospective perioperative database containing demographic, sur-
gical, hemodynamic, laboratory, and nutritional data for all pa-
tients who underwent S1P was reviewed. Patient-related variables
assessed included age, sex, weights at birth and at S1P, diagnostic
category, ascending aortic diameter, need for preoperative me-
chanical ventilation or inotropic support before S1P, and feeding
method at time of hospital discharge. Operative variables included
cardiopulmonary bypass time, deep hypothermic circulatory arrest
time, total support time (defined as cardiopulmonary bypass time
plus deep hypothermic circulatory arrest time), and shunt size.
Hemodynamic variables compared during the first 48 postopera-
tive hours included arterial and venous oxygen saturations, arte-
riovenous oxygen content difference, Qp/Qs, hemoglobin, mean
blood pressure, central venous pressure, and anaerobic threshold.
Variables assessed at the time of S2P included age, weight, and
preoperative oxygen saturation. Outcome measures were operative
survival after S1P and survival to S2P.
Interstage weights and SpO2 were obtained at periodic clinic
visits for patients who were discharged home without home sur-
veillance (group A, n 57) and were compared with prospectively
collected data from patients discharged with home monitoring
equipment (group B, n  24). Interstage SpO2 and weight were
compared between the two groups. Fixed effects regression models
were used to compare differences in SpO2 between groups A and
B, as well as within group B for comparison of patients who did
versus did not undergo any intervention as a result of home
monitoring.
Statistical analysis was completed with SPSS advanced Models
9.0 (SPSS, Inc, Chicago, Ill) and STATA software (Stata Corpo-
ration, College Station, Tex). Descriptive statistics are presented as
mean  SD or percentage and count unless otherwise indicated.
Median values are reported where appropriate. Variables were
analyzed with 2 statistics for categorical variables and analysis of
variance techniques for continuous variables. Actuarial survival
analysis was performed with Kaplan-Meier methods with log-rank
comparison of cumulative survival by group. A polynomial regres-
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sion equation was generated to plot patient growth between S1P
and S2P (SPSS).
Results
Follow-up data were available for 100% of the patients
through May 2002. Early survival after S1P was 90.4%
(57/63) for group A and 100% (24/24) for group B. Inter-
stage mortality among survivors to hospital discharge be-
fore S2P was 15.8% (9/57) in group A and 0% (0/24) in
group B (P  .039). Survival from birth through S2P was
74.6% (48/63) in group A and 100% (24/24) in group B (P
 .01; Figure 1). In the home surveillance group (group B),
the age at S2P was younger, 4.31.6 months compared with
5.6  2.1 months in group A (P  .016). Thirteen of 24
patients in the home surveillance group (group B) breached
home monitoring criteria. These 13 group B patients under-
went earlier S2P (3.7 1.1 months of age) than the remaining
11 patients (5.2 2.0 months of age; P .028). The 11 group
B patients who did not breach surveillance criteria underwent
S2P at an age that was not different from that of patients in
group A (5.2  2.0 months vs 5.6  2.1 months). There was
1 in-hospital death among patients undergoing S2P in group A;
there were no in-hospital deaths in group B.
Patient and Operative Variables
The anatomic diagnoses did not differ between groups and
are shown in Table 1. During this study period, no patient
was deemed to be ineligible for or denied S1P, and no
patient underwent heart transplant as primary therapy. S1P
was declined by the parents of one neonate with HLHS and
multiple congenital anomalies. Five other patients with ex-
tracardiac anomalies, all from group A, underwent success-
ful S1P, with 4 of 5 patients surviving to S2P. A patient with
Turner syndrome died before S2P. The extracardiac anom-
alies of the interstage survivors included tracheoesophageal
fistula with foramen of Morgagni diaphragmatic hernia,
cystic fibrosis, ciliary dysmotility, and chromosome 15
long-arm deletion. Aortic atresia with mitral atresia or ste-
nosis was the predominant diagnosis in each group of pa-
tients discharged to home after S1P: 33 of 57 (61.4%) in
group A and 15 of 24 (62.5%) in group B. There was a trend
toward smaller ascending aortic diameter in group B pa-
tients (2.67  0.99 mm vs 3.42  1.67 mm, P  .06). The
finding of ascending aortic diameter less than or equal to 2
mm was not different between groups: 40% in group A and
55% in group B. Prenatal diagnosis of HLHS was increas-
ingly common in the more recent cohort (62% in group B vs
19% in group A; P  .001). The groups did not differ in
gender, need for preoperative mechanical ventilation or
inotropic support, or age or weight at the time of S1P.
Cardiopulmonary bypass time was significantly longer in
group B (125.4  48.0 minutes vs 171.1  47.1 minutes, P
 .001), with correspondingly shorter circulatory arrest
time (59.8  17.0 minutes vs 8.3  3.0 minutes, P  .001;
Table 2). The differences in cardiopulmonary bypass and
circulatory arrest times between groups reflect the use of
continuous cerebral perfusion in group B. However, total
support times did not differ between groups (183.3  56.0
minutes vs 179  47.3 minutes). Postoperative arterial and
venous oxygen saturations, arteriovenous oxygen content
Figure 1. Survival curve calculated by Kaplan-Meier method for
patients between S1P and S2P. Interstage survival was signifi-
cantly improved in group B.
TABLE 1. Anatomic diagnoses, group A versus group B
Diagnostic category
Group A
(n  63)
Group B
(n  24)
HLHS 45 (71.5%) 19 (79.2%)
Aortic atresia with mitral atresia
or mitral stenosis
35 15
Aortic stenosis with mitral
atresia or mitral stenosis
10 4
Hypoplastic left hear variant 18 (28.5%) 5 (20.9%)
HLHS with ventricular septal
defect
7 1
Heterotaxy 3 0
Unbalanced atrioventricular
canal
1 1
Complex double-outlet right
ventricle
3 0
Tricuspid atresia with
transposition of the great
arteries
1 1
Double-inlet left ventricle with
transposition of the great
arteries
3 2
Differences between groups in proportions of HLHS and hypoplastic left
heart variant diagnosis were not significant.
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difference, Q˙ p/Q˙ s, hemoglobin, mean blood pressure, cen-
tral venous pressure, and anaerobic threshold did not differ
between groups during the first 48 hours.
Outpatient Variables
Atrioventricular valve insufficiency (moderate or greater)
was present at hospital discharge in 17.5% of patients in
group A and 25% of patients in group B. Ten patients in
group A (17.5%) were discharged home with supplemental
oxygen, as were 4 patients in group B (16.7%). Mean SpO2
values at discharge were 81.1%  4.2% in group A and
82.4%  2.8% in group B. At the time of S2P, SpO2 values
were 74.2% 6.0% in group A and 72.5% 5.4% in group
B. Within group B, patients who underwent an intervention
as a result of increased cyanosis detected at home were
more hypoxemic at S2P than were those patients who did
not have increased cyanosis detected at home (SpO2 75.8%
 3.5% vs 69.8%  5.4%, P  .005; Table 3). Figure 2
illustrates the decrease in SpO2 that prompted intervention in
the home surveillance group relative to the SpO2 trend in
group B patients who had no home-detected events (P 
.001 by fixed effects regression).
Weight at hospital discharge after S1P was not different
between groups: 3.35  0.63 kg in group A versus 3.21 
0.40 kg in group B. Gastrostomy tubes were placed in 28%
of the patients in group A and 25% of patients in group B.
Despite younger age at S2P for group B, weight at the time
of S2P was not different between groups (5.70  1.35 kg in
group A vs 5.34 0.80 kg in group B; Table 3). From more
than 1400 patient weights obtained for the entire cohort, a
polynomial regression equation was generated to estimate
patient growth between S1P and S2P (Figure 3). Average
daily weight gain of the cohort was 20 g/d. The growth
curve generated demonstrated a slowing of growth velocity
between 4 and 5 months of age.
Mortality and Interstage Interventions in Group A
Interstage mortality in group A was 15.8% (9/57), with all
deaths occurring at less than 120 days of age (Figure 4).
Autopsy data were available for 3 of 9 patients. Clinical
impressions and echocardiographic findings before and at
the time of death were obtained through chart reviews for all
9 patients. Aortic atresia was the diagnosis in 78% of the
interim death group (7/9). Interstage death was associated
with residual or recurrent lesions, concurrent illness, or
feeding difficulties. Some patients had more than one prob-
lem. One patient with aortic atresia, mitral stenosis, and
Turner syndrome underwent balloon dilatation of distal
shunt obstruction before discharge after S1P. She subse-
quently had progressive tricuspid insufficiency and ventric-
ular dysfunction develop. This was the only patient with a
residual lesion identified before hospital discharge. Two
other patients, both with aortic and mitral atresia, had out-
patient echocardiographic findings of narrowing at the distal
end of the shunt and moderate tricuspid regurgitation. One
of these patients also had concomitant neoaortic coarctation
gradient of 60 mm Hg. Among the remaining 6 patients, we
did not identify shunt obstruction, arch obstruction, or com-
promise of the atrial septal defect. Two patients with no
prodromal illness died suddenly at home. One of these
patients was known to have moderate tricuspid regurgita-
TABLE 2. Patient and operative characteristics at S1P,
group A versus group B
Variable
Group A
(n  63)
Group B
(n  24) P value
Gender (% male) 65% 54% NS
Age at S1P (d) 8.1 9.0 6.4 4.9 NS
Weight at S1P (kg) 3.17 0.56 3.15 0.34 NS
Aortic diameter
(mm)
3.42 1.67 2.67 0.99 .06
Cardiopulmonary
bypass time
(min)
125.4 48.0 171.1 47.1 .001
Circulatory arrest
time (min)
59.8 17.1 8.3 3.0 .001
Total support time*
(min)
185.3 56.0 179.4 47.3 NS
Median shunt size
(mm)
3.5 3.5 NS
Hospital stay (d) 35 19 31 13 NS
Early survival (%) 90.4% 100% NS
Values are mean  SD unless otherwise indicated. NS, Not statistically
significant.
*Cardiopulmonary bypass time plus deep hypothermic circulatory arrest
time.
Figure 2. SpO2 trends for group B. Locally weighted polynomial
regression lines and 95% confidence interval are indicated. This
illustrates that patients in group B who underwent intervention
because of home-detected events had decline in SpO2 not seen in
patients without events detected at home and who did not require
early intervention. Patients who had events detected had signif-
icantly lower SpO2 than those who did not (P < .001 by fixed exact
regression).
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tion. Three patients had evidence of a respiratory illness at
the time of death. Two of these patients had respiratory
infection confirmed at autopsy, 1 with unspecified viral
pneumonia and 1 with Pneumocystis carinii pneumonia.
Four patients had feeding difficulties. One patient, with a
several day history of decreased oral intake, died suddenly
a week after diuretic therapy was increased. One patient in
group A was seen at 111 days of age critically ill and in
shock with decreased SpO2 after a 2-day history of diarrhea.
This patient underwent emergency S2P for what was
thought to be impending shunt thrombosis. This patient was
noted to have ischemic necrosis of the bowel in the oper-
ating room at the end of the procedure. Bowel ischemia
confirmed by pathologic examination was determined to
have predated the S2P procedure and was not due to em-
bolism or thrombosis of the superior mesenteric artery but
rather was consistent with hypovolemia. This was the only
in-hospital death among any of the patients undergoing S2P.
Although this was not strictly an interstage death, the mech-
anism of death was consistent with those observed in the
interstage mortality group.
Interventions for recurrent arch obstruction were per-
formed in 33% of the patients in group A (19/57). Interven-
tional catheterization with balloon angioplasty for recurrent
arch obstruction was performed in 3 of 57 (5.3%). Surgical
arch revision was performed in 3 of 57 patients (5.3%)
before S2P, whereas 13 of 57 (22.8%) underwent arch
revision at the time of S2P. None of the patients who
underwent balloon angioplasty had subsequent surgical arch
revision at S2P.
Mortality and Interstage Interventions in Group B
All patients discharged with home monitoring of SpO2 and
weight survived to S2P. Data obtained through home sur-
veillance found 13 of 24 patients at increased risk: 12
patients with worsening hypoxemia from baseline and 1
patient with poor feeding and poor growth without worsen-
ing hypoxemia.
Outpatient detection of desaturation from baseline, as
illustrated in Figure 2, was the predominant cause for in-
tervention in group B and occurred 14 times in 12 of 24
home surveillance subjects. Parents of all but 3 patients
sought medical attention at age less than 100 days (range
41-99 days, median 69 days) as the result of breach of home
surveillance criteria. Two of 12 patients were hospitalized at
41 and 88 days of age with cough, congestion, hypoxemia,
and need for frequent nasopharyngeal suctioning, consistent
with bronchiolitis (1 had a positive culture for respiratory
syncytial virus). These 2 patients each were seen a second
time by the cardiologist for increased cyanosis without an
associated respiratory illness, which led to a diagnostic
cardiac catheterization and subsequent S2P at the ages of
113 and 108 days. Of the remaining 10 patients with in-
creased interstage cyanosis detected at home, all underwent
cardiac catheterization within 7 days of presentation (me-
dian age 78 days, range 59-182 days). Eight patients under-
went catheterization at less than 100 days of age. Seven
patients underwent subsequent S2P within 3 days of cathe-
terization, and 1 patient underwent balloon angioplasty of
the systemic to pulmonary artery shunt at 69 days of age
with subsequent S2P performed at 129 days of age because
of poor growth. Among the 7 patients who had subsequent
S2P within 3 days of catheterization, 2 patients were found
to have narrowing of the origin of the innominate artery
from which the systemic to pulmonary shunt arose and 3
patients had distal shunt narrowing. Two patients without
residual or recurrent anatomic lesions and without obstruc-
tion of shunt flow were thought to be favorable candidates
for early S2P and underwent subsequent palliation at ages
79 and 90 days of age because of unacceptable cyanosis.
Another of the 10 patients with increased interstage cyano-
sis was not found to have a recurrent or residual anatomic
TABLE 3. Patient characteristics at S1P discharge and S2P
Variable
Group A
(n  57)
Group B
(n  24) P value B0 (n  11) B1 (n  13) P value
Gastric tube placement (%) 28% 25% NS 27% 23% NS
S1P discharge weight (kg) 3.4 0.6 3.2 0.4 NS 3.1 0.4 3.3 0.4 NS
Weight at S2P (kg) 5.7 1.3 5.3 0.8 NS 5.4 0.8 5.3 0.8 NS
Home oxygen therapy 17.5% 16.7% NS 8.3% 8.3% NS
SpO2 at discharge (%) 81.1 4.2 82.4 2.8 NS 82.8 2.1 82.2 3.5 NS
SpO2 at S2P (%) 74.2 6.0 72.5 5.4 NS 75.8 3.5 69.8 5.4 .005
Age at S2P (mos) 5.6 2.1 4.3 1.6 .016 5.2 2.0 3.7 1.1 .028
Survival to S2P 76% 100% .01 100% 100% NS
Hospital stay for S2P (d) NS
Mean 13 13 13 21 NS 16 25 9 3
Median 8 8 7 8
Comparisons are group A versus group B and within group B between patients without an intervention as a result of home surveillance (B0) versus those
with an intervention (B1). Values are mean  SD unless otherwise indicated. NS, Not statistically significant.
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lesion at 59 days of age but was responsive to oxygen. He
was thought to have medical lung disease and was dis-
charged home with supplemental oxygen to undergo S2P
2.5 months later. One patient who had an elective preoper-
ative diagnostic catheterization was admitted 2 weeks be-
fore scheduled S2P for earlier intervention related to wors-
ening hypoxemia. In 8 of 24 home surveillance patients,
interval hypoxemia led to S2P at less than 100 days of age.
Figure 3. Interstage patient growth among survivors to S2P was calculated with more than 1400 observations of
patient weight between S1P and S2P. Regression line and 95% confidence intervals are indicated. Curve indicates
limited growth potential after S1P of HLHS. In this group of patients, unlike healthy infants in whom continued
growth is expected, growth into later infancy was limited. This is further evidence of interstage period risk.
Figure 4. Timeline of interstage mortality and risk factors for group A. Only one patient died suddenly without
residual or recurrent lesions or antecedent illness. Tricuspid insufficiency indicates insufficiency graded as
moderate or greater in severity. AA, Aortic atresia; MA, mitral atresia; TR, tricuspid regurgitation; PCP, P carinii
pneumonia; MS, mitral stenosis; AS, aortic stenosis; MA, mitral atresia; DORV, double-outlet right ventricle.
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Weight loss criteria were not violated by any patient, nor
was any patient noted to have gastrointestinal losses. Of the
12 patients with increased interstage cyanosis, 4 (all less
than 100 days old at 55, 69, 76, and 92 days) also had
decreased feeding and poor weight gain reported. The pa-
tient who was seen at 55 days of age with poor feeding
underwent gastrostomy tube placement for nutritional sup-
port. One patient with poor feeding and poor growth who
did not have concomitant desaturations from baseline un-
derwent cardiac catheterization followed by S2P with arch
reconstruction at 113 days of age. No patient in group B
underwent interventional catheterization for recurrent arch
obstruction or surgical arch reconstruction before S2P; how-
ever, 6 of 24 patients (25%) underwent arch reconstruction
at the time of S2P.
Discussion
The effectiveness of staged single-ventricle palliation for
HLHS has been limited by high mortality. Improved post-
operative management that focuses on control of the Q˙ p/Q˙ s
combined with early detection of inadequate perfusion has
resulted in improved S1P survival.5-7 Mortality before S2P
remains high, and it is unclear whether improvements in
S1P management have affected this high-risk interstage
period.1,2 Even the optimal S1P patient continues to have
physiologic risks, specifically parallel circulation, volume
overload to the single ventricle, and cyanosis. The introduc-
tion of S2P as an intermediate step in single-ventricle pal-
liation was a milestone that resulted in improved survival
and allowed the practical application of the Fontan pathway
to patients with HLHS. The benefits of S2P include relief of
excess volume load and improvement in arterial saturation.
The S2P procedure is well tolerated in this group of patients,
with low mortality and short hospital stays. After S2P,
patients are at substantially decreased risk of death, show
improved growth, have better tolerance of concurrent ill-
ness, and are low-risk candidates for a completion Fontan
operation.8-11 The optimal timing of S2P has not been
determined. Although patients younger than 4 weeks toler-
ate S2P poorly, infants as young as 8 weeks with satisfac-
tory preoperative hemodynamics have undergone S2P suc-
cessfully.12 Earlier relief of volume overload and
improvement in cyanosis may be especially important in the
patient with a single right ventricle with limited ability to
increase cardiac output and a tricuspid valve prone to de-
velopment of insufficiency when exposed to prolonged vol-
ume or pressure overload.
During the interstage period, patients are at risk for
development of recurrent lesions, such as shunt stenosis or
arch obstruction, that may be subtle and have important
consequences. Jonas3 has previously described restrictive
atrial septal defect, neoaortic arch obstruction, pulmonary
artery distortion, and tricuspid valve insufficiency as ana-
tomic abnormalities that may contribute to attrition after
successful S1P. In a series of postmortem evaluations, Bar-
tram and colleagues13 confirmed these findings, noting re-
sidual or recurrent lesions in 44 of 122 deaths (36%).
Any process that causes an imbalance in the oxygen
supply-demand relationship will result in decreased arterial
oxygen saturation in the patient with parallel circulation. An
example of this is respiratory infection, which may result in
pulmonary venous desaturation and worsening cyanosis be-
cause of impaired respiratory mechanics resulting from se-
cretions, airway edema, and pneumonitis. This would sup-
port previous reports of viral illnesses as a cause of death in
patients after S1P.4,13,14 In this study, of the 9 interstage
deaths before implementing the home surveillance program,
4 (44%) patients had symptoms of a respiratory illness or
dehydration. Gastroenteritis, a common illness in infants,
may result in acute dehydration. In the patient with single-
ventricle anatomy after S1P, the resulting increase in sym-
pathetic tone will lead to further reduction of systemic flow
as Q˙ p/Q˙ s increases. One additional patient who died after
emergency S2P had evidence of a preoperative gastrointes-
tinal pathologic condition that might have been identified
through acute weight loss. Indeed, it was this patient who
motivated us to develop a home surveillance program.
The primary goal of the home surveillance program was
to develop a simple, reliable strategy to detect worsening
systemic oxygenation and acute dehydration. Patients were
discharged with infant scales, to identify dehydration
through acute weight loss as well as growth failure through
lack of weight gain, and with pulse oximeters, to identify
worsening desaturation. These were devices with which the
parents were already familiar and that were straightforward
to use. The criteria for contacting a physician were deter-
mined by consensus as representing the physiologic limits
beyond which survival would be in jeopardy and included
SpO2 less than 70% and acute weight loss of 30 g or failure
to gain 20 g during 3 days. Worsening desaturation was the
most common indication for contacting a physician and
occurred in 50% of the patients (12/24). No patient had
acute dehydration or the clinical appearance of gastroenter-
itis, but isolated poor weight gain resulted in a gastrostomy
tube in 1 patient and early S2P with repair of recurrent arch
obstruction in another. Overall timing of S2P was earlier in
group B than group A (5.6  2.1 months vs 4.3  1.6
months, P  .016). Of significant interest, though, is the
intragroup analysis of group B patients. In 13 of 24 patients
with evidence of increased vulnerability (54%), as detected
by decreased SpO2 or slowed weight gain, progression to
S2P occurred significantly earlier than in the remaining 11
patients in group B who had no detectable problems at home
(3.7  1.1 months vs 5.2  2.0 months, P  .028).
Additionally, the age at S2P of group B patients who did not
breach surveillance criteria was not different from the age of
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S2P for group A patients (5.2  2.0 months vs 5.6  2.1
months).
A growth curve that included more than 1400 data points
was developed for all the survivors to S2P. Unlike the
growth curve of a healthy infant, who usually doubles the
birth weight by 5 months of age, the patient with HLHS who
has undergone S1P appears to have limited growth poten-
tial, with a plateau phase of weight gain after 150 days
(Figure 3). This limited growth potential provides further
evidence of the increased risk of the interstage period.
Interestingly, although group A patients were older at the
time of the S2P, they weighed the same as the patients in
group B. The group A patients may have been subjected to
a period of prolonged cyanosis and volume overload with-
out the benefit or perhaps even the possibility of additional
weight gain. This poor growth potential after 4 to 5 months
calls into question the value of routinely delaying S2P
beyond 5 months of age.
Previous studies have identified aortic atresia and smaller
ascending aortic diameter as risk factors for late death after
S1P.15-17 This anatomic subtype represents the most ex-
treme form of HLHS, presumably with the lowest physio-
logic reserve. There were no differences in anatomic sub-
types between groups, although there was a trend toward
smaller ascending aortic size in the home surveillance
group. Thus the survival advantage in group B was not
based on favorable anatomy.
The data suggest that frequent monitoring of SpO2 and
weight were useful in selecting patients at increased risk
during the interstage period. In the patient with single-
ventricle anatomy and parallel circulation, arterial satura-
tion is a function, among other things, of hemoglobin,
pulmonary venous saturation, Q˙ p/Q˙ s and total cardiac out-
put. Therefore, diminished SpO2 may be particularly sensi-
tive and will discriminate patients with anemia, respiratory
infection, decreased total cardiac output, as well as de-
creased Q˙ p/Q˙ s. It is more difficult to develop a home
surveillance strategy to reliably detect recurrent arch ob-
struction. Recurrent arch obstruction, however, might be
identified through the more subtle symptom of slow weight
gain.
The home surveillance program was associated with
improved interstage survival; however, this study has im-
portant limitations. This study compared noncontemporary
groups, although it should be noted that preoperative and
postoperative management was uniform and postoperative
hemodynamics did not differ between groups. Modification
of surgical technique, more specifically implementation of
continuous cerebral perfusion, resulted in shorter circula-
tory arrest time in the more recent cohort and may be
implicated as a variable that improved interstage survival.
We cannot rule out the impact of prenatal diagnosis on
interstage survival. This study was neither blinded nor ran-
domized, and therefore we cannot definitively conclude that
lack of intervention in patients who breached surveillance
criteria would have resulted in death. Overall progression
along an institutional learning curve also probably contrib-
uted to improved outcomes in the home surveillance group.
Despite these limitations, criteria selected to prompt exam-
ination were not different from those that would have trig-
gered investigation in either group if identified at a routine
clinic visit. In addition, it is important to note that the
development of desaturation and poor weight gain occurred
abruptly during the course of several days, a shorter interval
than even reasonably spaced clinic visits.
The success of a home surveillance program requires
dedicated family participation, as well as collaboration
among multidisciplinary health care providers, which may
be challenging for a given patient. Obtaining reliable data
through appropriate equipment use is necessary for ade-
quate assessment of physiologic variances and could prove
to be a limitation. These patients frequently have a pro-
longed intensive care unit course, and parents become fa-
miliar with the concept and measurement of SpO2. We were
impressed that parents came to identify episodes and rec-
ognize the significance of decreased saturation while their
children were in the hospital. They appeared to be reassured
when arterial saturations were in an acceptable range. The
psychosocial impact of home SpO2 and weight monitoring
was not formally evaluated. Given the risk of interstage
death, however, we suspect that families have taken comfort
in having objective data as an indicator of their children’s
condition.
Improvements in S1P operative survival were, in our
experience, the result of objective assessment of the pa-
tients’ circulatory status through improved physiologic
monitoring. In this study improvement in interstage survival
was also the result of continued collection of objective data
through home surveillance to select patients at risk for
interstage death. In this small series, we discriminated pa-
tients who were at increased risk for interstage death be-
cause of concurrent illness or residual or recurrent lesions.
Early S2P was the primary strategy used to treat this sub-
group of patients who appeared to be in jeopardy during the
interstage period. It is clear from our experience and those
of others that although S2P can be successfully accom-
plished in patients as young as 6 weeks, the postoperative
course in these patients is prolonged relative to older pa-
tients. We must assume that the very young patient is at
increased risk for death after S2P. Thus proposing early S2P
for everyone, rather than reserving this therapy for those in
whom the risk-benefit ratio is favorable, may in fact com-
pound morbidity and mortality. Because growth appears to
plateau between 4 and 5 months of age, we can conclude
that S2P should be completed no later than 5 months of age.
Continued data collection and follow-up are necessary to
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determine whether these short-term improvements will re-
sult in improved long-term outcomes. We continue to use
home surveillance to discriminate patients at risk for inter-
stage death.
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Discussion
Dr J. William Gaynor (Philadelphia, Pa). I congratulate Gha-
nayem and coauthors on this excellent report addressing the im-
portant and troubling issue of interstage mortality after successful
S1P. This is yet another important contribution to the management
of these difficult cases from your institution.
In this study, detection of home-monitored events, either de-
creased oxygen saturation or poor weight gain, led to earlier
evaluation of these patients and frequently earlier performance of
the superior cavopulmonary connection. There was no interstage
mortality in the relatively small group of infants for whom home
monitoring was used.
Dr Ghanayem, I have several questions. First, we recently
reviewed risk factors for death after S1P in 158 infants during a
3.5-year period. In 46% of these infants there were additional risk
factors, such as low birth weight (2.5 kg); presence of additional
cardiac defects at the time of S1P, such as interrupted aortic arch,
moderate to severe tricuspid regurgitation, and anomalies of pul-
monary or venous drainage; or presence of major extracardiac
anomalies or genetic syndromes.
The interstage mortality in that series was approximately 10%,
similar to your group A. In a multivariable analysis, the strongest
predictors of interstage mortality were the presence of additional
cardiac defects and the presence of an extracardiac anomaly or
genetic syndrome. In your series, how many infants had either
additional cardiac defects or extracardiac anomalies? And what
was the impact of these associated anomalies on interstage mor-
tality?
Second, it would appear that in group A several of the deaths
occurred at a relatively early age, 50 to 70 days. These deaths
appeared to occur before the age at which home monitoring events
were detected in group B and before the age at which most group
B patients underwent cavopulmonary connection. Do you attribute
the lack of these early deaths and this decreased very early mor-
tality to the home monitoring program, or does this simply repre-
sent increasing institutional experience with the management of
these infants or some other change in management?
Third, an intriguing finding of your study is the decrease in
growth velocity at approximately 5 months of age. This implies
that there may be no advantage to delaying cavopulmonary con-
nection even for children who are doing relatively well. What is
your current policy for timing of cavopulmonary connection for
children who have no home monitoring events and are otherwise
doing well?
Fourth, the presence of aortic atresia, particularly with a dimin-
utive ascending aorta, is a potential risk factor for coronary isch-
emia and interstage mortality. What was the incidence of very
small ascending aorta, less than 2 mm, in your series? Was there
any difference between group A and group B?
Finally, I was intrigued by the fact that many of your patients
with recurrent arch obstruction undergo surgical intervention
rather than balloon dilatation of the arch. What are your reasons for
choosing surgical reconstruction rather than balloon dilatation?
I again congratulate you on your excellent study.
Dr Ghanayem. Thank you, Dr Gaynor, for your remarks. The
presence of additional cardiac defects, such as preoperative mod-
erate to severe tricuspid regurgitation, anomalous origin of the
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